Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Knowing what percentages to allocate to stocks and bonds helps in portfolio balance. Learn effective allocation strategies today.
28,656 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Could canopy growth stock realistically quadruple from here? This deep-dive walks through the bull case, the risks, a...
Powell Industries stock soars after a significant stake increase by a prominent fund, driving a 161% annual gain. Thi...
Stock splits can make a popular stock feel more approachable, but they don’t change the business. Read on to see how ...
With Broadcom set to report earnings, investors are weighing momentum in AI infrastructure against valuation. This gu...
NuScale Power has sparked excitement around small modular reactors, but does the hype translate into real investing u...
Qualcomm nudges the industry toward 6G with a bold roadmap. Investors are weighing the potential for faster networks ...
Rivian just raised guidance, signaling progress in its production ramp. Yet the stock reaction was bearish, underscor...
When a beverage maker expands beyond a single hero brand, the investment narrative changes. Celsius transformed its g...
In February, Occidental Petroleum’s stock surged nearly 17%, powered by higher oil prices and strong earnings signals...
Two popular tech ETFs sit on opposite ends of the spectrum: a broad technology exposure semiconductor approach with V...
A major hedge fund trimmed its ZoomInfo position by millions, fueling questions about the company's prospects. This a...